Skip to main content
NCBI home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2005 Sep;82(3):468–478. doi: 10.1093/jurban/jti094

Risk factors for hepatitis B in an outbreak of hepatitis B and D among injection drug users

Stephanie R Bialek 1,✉, William A Bower 1, Karen Mottram 2, Dave Purchase 3, T Nakano 1, Omana Nainan 1, Ian T Williams 1, Beth P Bell 1
PMCID: PMC3456050  PMID: 16049202

Abstract

During January–April, 2000, 12 cases of acute hepatitis B were reported in Pierce County, Washington, compared with seven in all of 1999. Seven (58.3%) case patients were injection drug users (IDUs), three of whom were coinfected with hepatitis D virus (HDV) and died of fulminant hepatitis. Vaccination clinics were implemented at the local health department and needle exchange program to control the outbreak. We investigated this outbreak to determine risk factors for hepatitis B virus (HBV) transmission among IDUs. Hepatitis B cases were ascertained through routine surveillance and prevaccination testing at vaccination clinics. We conducted a case-control study comparing IDU case patients with HBV-susceptible IDUs identified at the vaccination clinics. Fifty-eight case patients were identified during January–December, 2000, 20 (34.5%) of whom were coinfected with HDV. Thirty-eight case patients (65.5%) reported current IDU. In the case-control study, the 17 case patients were more likely than the 141 controls to report having more than one sex partner [odds ratio (OR)=4.8, 95% confidence interval (CI)=1.5–15.0], injecting more than four times a day (OR=4.5, 95% CI=1.2–15.6) and sharing drug cookers with more than two people (58.8% vs. 14.0%, OR=14.0, 95% CI=2.4–81.5). Results were similar after controlling for syringe sharing in multivariable analysis. IDUs should be vaccinated against hepatitis B and should be advised against sharing drug injection equipment.

Keywords: Hepatitis B, Hepatitis D, Intravenous drug abuse

Full Text

The Full Text of this article is available as a PDF (131.3 KB).

Footnotes

None of the authors have any financial arrangements with any company whose product is pertinent to this manuscript.

References

  • 1.Hepatitis Surveillance Report 57. Atlanta, GA: CDC; 2000. [Google Scholar]
  • 2.Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655–661. doi: 10.2105/ajph.86.5.655. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Murrill CS, Weeks H, Castrucci BC, et al. Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities. Am J Public Health. 2002;92:385–387. doi: 10.2105/AJPH.92.3.385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26:703–707. doi: 10.1081/ADA-100101903. [DOI] [PubMed] [Google Scholar]
  • 5.Lopez-Zetina J, Kerndt P, Ford W, et al. Prevalence of HIV and hepatitis B and selfreported injection risk behavior during detention among street-recruited injection drug users in Los Angeles County, 1994–1996. Addiction. 2001;96:589–595. doi: 10.1080/09652140020031638. [DOI] [PubMed] [Google Scholar]
  • 6.Polish LB, Gallagher M, Fields HA, et al. Delta hepatitis: molecular biology and clinical and epidemiological features. Clin Microbiol Rev. 1993;6:211–229. doi: 10.1128/cmr.6.3.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.DesJarlais C, Perlis T, Friedman SR, et al. Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990–1997. Am J Public Health. 2000;90:1112–1116. doi: 10.2105/ajph.90.7.1112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Crofts N, Aitken CK. Incidence of bloodborne virus infection and risk behaviours in a cohort of injecting drug users in Victoria, 1990–1995. Med J Aust. 1997;167:17–20. doi: 10.5694/j.1326-5377.1997.tb138757.x. [DOI] [PubMed] [Google Scholar]
  • 9.Cook PA, McVeigh J, Syed Q, et al. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment. Addiction. 2001;96:1787–1797. doi: 10.1046/j.1360-0443.2001.961217878.x. [DOI] [PubMed] [Google Scholar]
  • 10.McCoy CB, Metsch LR, Chitwood DD, et al. Parenteral transmission of HIV among injection drug users: assessing the frequency of multiperson use of needles, syringes, cookers, cotton, and water. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:S25–S29. doi: 10.1097/00042560-199802001-00006. [DOI] [PubMed] [Google Scholar]
  • 11.Thiede H, Romero M, Bordelon K, et al. Using a jail-based survey to monitor HIV and risk behaviors among Seattle area injection drug users. J Urban Health. 2001;78:264–278. doi: 10.1093/jurban/78.2.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Hunter GM, Donoghoe MC, Stimson GV, et al. Changes in the injecting risk behaviour of injecting drug users in London, 1990–1993. AIDS. 1995;9:493–501. [PubMed] [Google Scholar]
  • 13.Hagan H, Thiede H. Changes in injection risk behavior associated with participation in the Seattle needle-exchange program. J Urban Health. 2000;77:369–382. doi: 10.1007/BF02386747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Koester S, Hoffer L. “Indirect sharing”: additional HIV risks associated with drug injection. AIDS Public Policy J. 1994;3:100–105. [Google Scholar]
  • 15.Mansson AS, Moestrup T, Nordenfelt E, et al. Continued transmission of hepatitis B and C viruses, but no transmission of human immunodeficiency virus among intravenous drug users participating in a syringe/needle exchange program. Scand J Infect Dis. 2000;32:253–258. doi: 10.1080/00365540050165875. [DOI] [PubMed] [Google Scholar]
  • 16.Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645–653. doi: 10.1093/aje/155.7.645. [DOI] [PubMed] [Google Scholar]
  • 17.Centers for Disease Control and Prevention Hepatitis B vaccination for injection drug users —Pierce County, Washington, 2000. MMWR Morb Mortal Wkly Rep. 2001;50:388–390. [PubMed] [Google Scholar]
  • 18.Nakano T, Shapiro CN, Hadler SC, et al. Characterization of hepatitis D virus genotype III among Yucpa Indians in Venezuela. J Gen Virol. 2001;82:2183–2189. doi: 10.1099/0022-1317-82-9-2183. [DOI] [PubMed] [Google Scholar]
  • 19.Nainan OV, Cromeans TL, Margolis HS. Sequence-specific, single-primer amplification and detection of PCR products for identification of hepatitis viruses. J Virol Methods. 1996;61:127–134. doi: 10.1016/0166-0934(96)02077-0. [DOI] [PubMed] [Google Scholar]
  • 20.Nainan OV, Stevens PE, Taylor PE, et al. Hepatitis B virus (HBV) antibody resistant mutants among mothers and infants with chronic HBV infection. In: Rizetto M, Purcell RH, Gerin JL, Verme G, et al., editors. Viral Hepatitis and Liver Disease. Turin, Italy: Edizioni Minerva Medica; 1997. pp. 132–134. [Google Scholar]
  • 21.Devereux J, Haeberli P, Smithies O. A comprehensive set of sequence analysis programs for the VAX. Nucleic Acids Res. 1984;12:387–395. doi: 10.1093/nar/12.1part1.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Abdala N, Reyes R, Carney JM, et al. Survival of HIV-1 in syringes: effects of temperature during storage. Subst Use Misuse. 2000;35:1369–1383. doi: 10.3109/10826080009148220. [DOI] [PubMed] [Google Scholar]
  • 23.Clatts MC, Heimer R, Abdala N, et al. HIV-1 transmission in injection paraphernalia: heating drug solutions may inactivate HIV-1. J Acquir Immune Defic Syndr. 1999;22:194–199. doi: 10.1097/00126334-199910010-00013. [DOI] [PubMed] [Google Scholar]
  • 24.Shah SM, Shapshak P, Rivers JE, et al. Detection of HIV-1 DNA in needle/syringes, paraphernalia, and washes from shooting galleries in Miami: a preliminary laboratory report. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;11:301–306. doi: 10.1097/00042560-199603010-00010. [DOI] [PubMed] [Google Scholar]
  • 25.Heimer R, Khoshnood K, Jariwala-Freeman B, et al. Hepatitis in used syringes: the limits of sensitivity of techniques to detect hepatitis B virus (HBV) DNA, hepatitis C virus (HCV) RNA, and antibodies to HBV core and HCV antigens. J Infect Dis. 1996;173:997–1000. doi: 10.1093/infdis/173.4.997. [DOI] [PubMed] [Google Scholar]
  • 26.Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981;1:550–551. doi: 10.1016/S0140-6736(81)92877-4. [DOI] [PubMed] [Google Scholar]
  • 27.Bueren J, Simpson RA, Jacobs P, et al. Survival of human immunodeficiency virus in suspension and dried onto surfaces. J Clin Microbiol. 1994;32:571–574. doi: 10.1128/jcm.32.2.571-574.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Alter MJ, Hadler SC. Delta hepatitis and infection in North America. Prog Clin Biol Res. 1993;382:243–250. [PubMed] [Google Scholar]
  • 29.Vlahov D, Junge B, Brookmeyer R, et al. Reductions in high-risk drug use behaviors among participants in the Baltimore needle exchange program. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:400–406. doi: 10.1097/00042560-199712150-00014. [DOI] [PubMed] [Google Scholar]
  • 30.Hagan H, DesJarlais DC, Purchase D, et al. An interview study of participants in the Tacoma, Washington, syringe exchange. Addiction. 1993;88:1691–1697. doi: 10.1111/j.1360-0443.1993.tb02044.x. [DOI] [PubMed] [Google Scholar]
  • 31.Hagan H, Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health. 1995;85:1531–1537. doi: 10.2105/ajph.85.11.1531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Hagan H, McGough JP, Thiede H, et al. Syringe exchange and risk of infection with hepatitis B and C viruses. Am J Epidemiol. 1999;149:203–213. doi: 10.1093/oxfordjournals.aje.a009792. [DOI] [PubMed] [Google Scholar]
  • 33.Hutchinson SJ, Goldberg DJ, Gore SM, et al. Hepatitis B outbreak at Glenochil prison during January to June 1993. Epidemiol Infect. 1998;121:185–191. doi: 10.1017/S0950268898001022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Stevenson J, Tannahill M, Biggs V. An outbreak of acute hepatitis B infection among injecting drug users in Inverclyde, Scotland. Commun Dis Public Health. 2001;4:60–63. [PubMed] [Google Scholar]
  • 35.Streetly A, Perkins A, Tucker KM, et al. An outbreak of hepatitis B among intravenous drug users in Medway. Community Med. 1988;10:147–155. [PubMed] [Google Scholar]

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES